<DOC>
	<DOCNO>NCT01455844</DOCNO>
	<brief_summary>The purpose study determine whether CaPre ( TM ) , give dos 1.0g 2.0g 12 week , effect fast plasma triglyceride patient mild high hypertriglyceridemia compare placebo .</brief_summary>
	<brief_title>TRIal For Efficacy Capre hyperTriglyceridemiA</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Male female adult age 18 75 year . Fasting plasma level TG â‰¥ 2.28 &lt; 10 mmol/L ( 200 877 mg/dL ) two occasion within 2 week ( screen prerandomization visit ) . Patients currently pharmacotherapy hyperlipidemia accord judgement physician Canadian Guidelines Diagnosis Treatment Dyslipidemia initiation drug therapy indicate duration study . Patients currently treat statin accord judgement physician Canadian Guidelines Diagnosis Treatment Dyslipidemia change current drug regimen indicate duration study . Patients treat statin must stable dose least 6 week prior screen . Patients willing follow NCEP Step 1 Diet ( see Appendix 4 ) duration study . Female participant childbearing potential ( i.e . surgically sterilize postmenopausal great one year ) must negative serum pregnancy test must use effective birth control method , define : 1. continuous use oral long act inject contraceptive least 2 month prior study entry , ; 2. use intrauterine device implantable contraceptive , ; 3. use double barrier method birth control Patients least 80 % compliant study medication placebo lead phase . Any concomitant medication opinion investigator would preclude patient successfully participate study . Women pregnant breast feeding . Participation another clinical trial within 30 day initiation study . Participants high risk cardiovascular disease ; ( The definition highrisk individual follow 2009 Canadian Guidelines include ) FRS &gt; = 20 % 10year risk ; b ) All patient uncontrolled diabetes ( DCA guideline ) c ) Evidence atherosclerosis evidence ascertain clinically indicate ) ; Systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg . In diabetic patient , systolic blood pressure &gt; 130 mmHg and/or diastolic blood pressure &gt; 90 mmHg . History stroke , intermittent claudication transient ischemic attack . Known unstable ( uncontrolled ) cardiac disease , within last 6 month . Patient clinically significant abnormal ECG screening . Patients uncontrolled diabetes mellitus , HbA1c &gt; 7.0 % . Known diagnosis hypoglycemia . Evidence active renal disease indicate fast estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/min per 1.73 m2 . Increased plasma level ( &gt; ULN ) amylase ( per respective lab upper limit ) / lipase ( &gt; 160 IU/L ) indication pancreatitis pancreatitis ( increase alcohol consumption , gallstone ) . History pancreatitis . Use lipid lower medication statin ezetimibe ( e.g niacin , fibrates ) and/or lipid lower NHP within 6 week prior screen visit . Intake &gt; 2 serving per week fish regiment use fish oil/omega3 supplement within 6 week prior screen visit . Known HIV Hepatitis B C positive . Patients uncontrolled asthma defined 2010 Consensus Summary Canadian Thoracic Society . Known seafood allergy allergy medicinal nonmedicinal ingredient study medication placebo , include : 1 . Omega3 fatty acid ( include EPA DHA ) 2 . Phospholipids ( mainly phosphatidylcholine ) 3 . Astaxanthin 4 . Microcrystalline cellulose Coagulopathy anticoagulant . Platelet aggregation inhibitor ( aspirin clopidogrel heparin ) permit study ; patient take aspirin clopidogrel permit study . Unable unwilling comply protocol . Patient report weight stable past 6 month ( within 3kg variation ) . Consumption 14 standard alcoholic drink week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hypertriglyceridemia</keyword>
</DOC>